NASDAQ:PRTA

Prothena Competitors

$23.02
-0.74 (-3.11 %)
(As of 04/20/2021 12:08 PM ET)
Add
Compare
Today's Range
$22.28
Now: $23.02
$23.65
50-Day Range
$20.62
MA: $23.76
$28.24
52-Week Range
$9.25
Now: $23.02
$28.66
Volume4,088 shs
Average Volume453,586 shs
Market Capitalization$920.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Competitors

Prothena (NASDAQ:PRTA) Vs. APLS, AVIR, EBS, TPTX, LEGN, and NKTR

Should you be buying PRTA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Prothena, including Apellis Pharmaceuticals (APLS), Atea Pharmaceuticals (AVIR), Emergent BioSolutions (EBS), Turning Point Therapeutics (TPTX), Legend Biotech (LEGN), and Nektar Therapeutics (NKTR).

Prothena (NASDAQ:PRTA) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Prothena and Apellis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prothena00703.00
Apellis Pharmaceuticals031112.87

Prothena currently has a consensus target price of $29.4286, indicating a potential upside of 30.85%. Apellis Pharmaceuticals has a consensus target price of $125.00, indicating a potential upside of 173.76%. Given Apellis Pharmaceuticals' higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Prothena.

Profitability

This table compares Prothena and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prothena-13,615.75%-41.97%-26.26%
Apellis PharmaceuticalsN/A-336.93%-78.28%

Volatility & Risk

Prothena has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Earnings and Valuation

This table compares Prothena and Apellis Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$810,000.001,136.96$-77,680,000.00($1.95)-11.81
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.87

Prothena has higher revenue and earnings than Apellis Pharmaceuticals. Prothena is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Prothena beats Apellis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares Prothena and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prothena-13,615.75%-41.97%-26.26%
Atea PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Prothena and Atea Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$810,000.001,136.96$-77,680,000.00($1.95)-11.81
Atea PharmaceuticalsN/AN/AN/AN/AN/A

Atea Pharmaceuticals has lower revenue, but higher earnings than Prothena.

Insider and Institutional Ownership

90.2% of Prothena shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Prothena and Atea Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prothena00703.00
Atea Pharmaceuticals00403.00

Prothena currently has a consensus target price of $29.4286, indicating a potential upside of 30.85%. Atea Pharmaceuticals has a consensus target price of $69.3333, indicating a potential upside of 65.04%. Given Atea Pharmaceuticals' higher possible upside, analysts plainly believe Atea Pharmaceuticals is more favorable than Prothena.

Prothena (NASDAQ:PRTA) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Insider & Institutional Ownership

90.2% of Prothena shares are held by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are held by institutional investors. 30.4% of Prothena shares are held by company insiders. Comparatively, 14.1% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Prothena and Emergent BioSolutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prothena00703.00
Emergent BioSolutions02502.71

Prothena currently has a consensus target price of $29.4286, indicating a potential upside of 30.85%. Emergent BioSolutions has a consensus target price of $113.6667, indicating a potential upside of 73.25%. Given Emergent BioSolutions' higher possible upside, analysts clearly believe Emergent BioSolutions is more favorable than Prothena.

Profitability

This table compares Prothena and Emergent BioSolutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prothena-13,615.75%-41.97%-26.26%
Emergent BioSolutions12.50%26.68%12.70%

Valuation and Earnings

This table compares Prothena and Emergent BioSolutions' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$810,000.001,136.96$-77,680,000.00($1.95)-11.81
Emergent BioSolutions$1.11 billion3.19$54.50 million$2.9122.60

Emergent BioSolutions has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Prothena has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Summary

Emergent BioSolutions beats Prothena on 8 of the 14 factors compared between the two stocks.

Turning Point Therapeutics (NASDAQ:TPTX) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Turning Point Therapeutics and Prothena's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-23.84
Prothena$810,000.001,136.96$-77,680,000.00($1.95)-11.81

Turning Point Therapeutics has higher earnings, but lower revenue than Prothena. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Turning Point Therapeutics and Prothena's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Turning Point TherapeuticsN/A-23.81%-23.08%
Prothena-13,615.75%-41.97%-26.26%

Analyst Ratings

This is a summary of recent recommendations and price targets for Turning Point Therapeutics and Prothena, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Turning Point Therapeutics00703.00
Prothena00703.00

Turning Point Therapeutics currently has a consensus target price of $153.7143, suggesting a potential upside of 117.85%. Prothena has a consensus target price of $29.4286, suggesting a potential upside of 30.85%. Given Turning Point Therapeutics' higher possible upside, equities research analysts clearly believe Turning Point Therapeutics is more favorable than Prothena.

Insider and Institutional Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. Comparatively, 90.2% of Prothena shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by company insiders. Comparatively, 30.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Prothena has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Summary

Prothena beats Turning Point Therapeutics on 6 of the 11 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Insider & Institutional Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 18.9% of Legend Biotech shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Prothena and Legend Biotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$810,000.001,136.96$-77,680,000.00($1.95)-11.81
Legend Biotech$64.39 million54.12$-132,970,000.00N/AN/A

Prothena has higher earnings, but lower revenue than Legend Biotech.

Profitability

This table compares Prothena and Legend Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prothena-13,615.75%-41.97%-26.26%
Legend Biotech-543.73%-205.60%-43.03%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Prothena and Legend Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prothena00703.00
Legend Biotech00303.00

Prothena presently has a consensus price target of $29.4286, suggesting a potential upside of 30.85%. Legend Biotech has a consensus price target of $49.00, suggesting a potential upside of 87.67%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Prothena.

Summary

Prothena beats Legend Biotech on 7 of the 10 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Volatility and Risk

Prothena has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500.

Insider and Institutional Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 95.3% of Nektar Therapeutics shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Comparatively, 3.0% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Prothena and Nektar Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prothena-13,615.75%-41.97%-26.26%
Nektar Therapeutics-269.05%-30.74%-22.63%

Analyst Ratings

This is a breakdown of current recommendations for Prothena and Nektar Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prothena00703.00
Nektar Therapeutics16102.00

Prothena currently has a consensus price target of $29.4286, suggesting a potential upside of 30.85%. Nektar Therapeutics has a consensus price target of $25.2857, suggesting a potential upside of 35.22%. Given Nektar Therapeutics' higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Prothena.

Earnings and Valuation

This table compares Prothena and Nektar Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$810,000.001,136.96$-77,680,000.00($1.95)-11.81
Nektar Therapeutics$114.62 million30.14$-440,670,000.00($2.52)-7.52

Prothena has higher earnings, but lower revenue than Nektar Therapeutics. Prothena is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Nektar Therapeutics beats Prothena on 8 of the 14 factors compared between the two stocks.


Prothena Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.79-0.4%$3.70 billionN/A-6.17
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$42.33-5.1%$3.68 billionN/A0.00Increase in Short Interest
Gap Down
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.78-3.2%$3.64 billion$1.11 billion21.15News Coverage
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$71.29-1.9%$3.56 billionN/A-20.31
LEGN
Legend Biotech
1.2$26.20-0.6%$3.46 billion$64.39 million0.00Analyst Report
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.95-0.8%$3.43 billion$114.62 million-7.64
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.08-1.0%$3.34 billion$306.98 million-6.74
Insmed logo
INSM
Insmed
1.2$31.88-1.2%$3.33 billion$136.47 million-12.26News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.99-1.3%$3.32 billion$339.08 million-12.20
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.14-0.1%$3.30 billion$26.52 million-8.03Unusual Options Activity
Alkermes logo
ALKS
Alkermes
1.2$20.42-1.8%$3.19 billion$1.17 billion-44.39Analyst Revision
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.47-1.5%$3.12 billion$36.13 million-67.87
Arvinas logo
ARVN
Arvinas
1.5$61.46-1.2%$3.04 billion$42.98 million-24.01Upcoming Earnings
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.58-0.1%$2.97 billion$80.43 million107.53
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$108.10-0.5%$2.94 billionN/A-53.78
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$76.02-0.1%$2.90 billion$644.77 million-10.84
OPKO Health logo
OPK
OPKO Health
1.9$4.14-1.4%$2.81 billion$901.90 million-23.00
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.14-0.6%$2.79 billion$421.03 million22.23
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.6%$2.69 billion$306.49 million25.58
Organogenesis logo
ORGO
Organogenesis
1.0$19.77-6.1%$2.69 billion$260.98 million-329.50Analyst Downgrade
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.82-0.8%$2.62 billion$182.24 million-8.54Analyst Upgrade
Insider Selling
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.62-0.9%$2.60 billion$25 million-9.12
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$42.35-2.4%$2.55 billionN/A-23.27
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.96-0.4%$2.54 billion$2.11 million-8.87Analyst Report
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$30.32-0.6%$2.44 billion$60,000.00-9.42Analyst Revision
News Coverage
Xencor logo
XNCR
Xencor
1.2$42.09-0.4%$2.43 billion$156.70 million-30.06
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$145.77-0.2%$2.43 billion$120.28 million-147.24Decrease in Short Interest
Cryoport logo
CYRX
Cryoport
1.7$49.54-2.0%$2.30 billion$33.94 million-85.41
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$31.90-0.5%$2.27 billion$15 million-16.70
ALX Oncology logo
ALXO
ALX Oncology
1.9$54.71-3.2%$2.27 billionN/A0.00
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.23-0.1%$2.25 billion$963.01 million14.05
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$30.15-3.5%$2.22 billion$23.90 million-18.73Analyst Report
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$51.89-1.5%$2.10 billionN/A0.00Analyst Report
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$24.75-5.4%$2.00 billion$103.54 million-18.61News Coverage
Amarin logo
AMRN
Amarin
1.6$5.01-0.6%$1.98 billion$429.76 million-100.18
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$26.87-1.4%$1.94 billion$410,000.00-5.84
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.45-0.9%$1.94 billionN/A-19.13
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.42-2.6%$1.94 billionN/A-11.24Gap Down
MacroGenics logo
MGNX
MacroGenics
1.2$33.46-4.8%$1.91 billion$64.19 million-10.69Analyst Report
Insider Selling
Decrease in Short Interest
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$57.89-1.4%$1.88 billionN/A-24.63Increase in Short Interest
Kura Oncology logo
KURA
Kura Oncology
1.6$27.71-0.3%$1.83 billionN/A-17.00
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$19.42-1.4%$1.80 billion$34.51 million-16.60
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.14-1.6%$1.77 billion$26.87 million-13.16Analyst Report
MORF
Morphic
1.3$54.28-0.3%$1.76 billion$16.98 million-34.79Decrease in Short Interest
FibroGen logo
FGEN
FibroGen
1.8$19.90-4.5%$1.75 billion$256.58 million-7.62
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.74-1.2%$1.71 billion$428.41 million15.57Analyst Upgrade
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.58-1.8%$1.70 billion$1.63 billion13.61
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$30.80-0.5%$1.64 billion$392.76 million12.78Analyst Upgrade
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.